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EVIDENCE-BASED MEDICINE METHODOLOGY –
SYSTEMATIC REVIEWS AND META-ANALYSES
W. Zhang
Nottingham University, Nottingham, United Kingdom
Meta-analysis was ﬁrst proposed by Glass (1976). The term
meta-analysis refers to the statistical methods to systematically
combine the outcomes of a series of different experiments or
investigations. Over 30 years of application and development,
meta-analysis has been established as a useful method in sum-
marizing research evidence for clinical decision-making. Con-
sequently, it becomes a major foundation for Evidence-Based
Medicine. Meta-analysis is also referred as quantitative review
(Greenland 1987) or systematic review (Peto 1987). The latter
denotes a full range of systematic assessment of clinical evi-
dence, not necessarily including statistical synthesis of evidence.
The contribution of meta-analysis in the management of os-
teoarthritis is apparent, from the conﬁrmation of the treatment
effects for exercise (Roddy 2005), to the comparative effective-
ness between acetaminophen and NSAIDs (Zhang 2004), as
well as the gastrointestinal toxicity of NSAIDs (Ofman 2002) and
more recently the cardiovascular side effects of rofecoxib (Juni
2004). It also raises questions such as whether topical NSAIDs
only work for OA in short-term period (Lin 2004), and whether
vascular side effects are the class effects of COX-2 inhibitors or
NSAIDs (Kearney 2006).
Whilst the merits of meta-analysis are recognized, it has some
pitfalls including publication bias and problems with heterogene-
ity. It is debated, for example, whether an overall pooling of
effect sizes of glucosamine from different trials irrespective of
quality would be adequate (Towheed 2005). Nevertheless, like
many other developments, meta-analysis continues to evolve
and contribute to the ﬁeld. It has become a major tool in the
development of treatment guidelines (Zhang 2005, 2007) and
has been extended to answer other clinical questions such as
diagnosis (Zhang 2006).
References will be provided upon request.
ANGIOGENESIS IN OA
D.A. Walsh
University of Nottingham, Academic Rheumatology, Nottingham,
United Kingdom
Purpose: To explain the relevance of inﬂammatory blood vessel
growth in OA
Methods: Synthesis of recent and historical data
Results: During OA, new blood vessels grow in synovium, at the
osteochondral junction and in osteophytes. Neovascularisation
can facilitate inﬂammation, degrade cartilage matrix, and lead to
new bone formation and sensory nerve growth. Different factors
appear to drive neovascularisation in different joint structures.
Inﬂammation, both in the synovium and within the subchondral
bone, stimulates angiogenesis by tipping the balance between
angiogenic and anti-angiogenic factors.
Conclusions: Addressing angiogenesis and the factors that
drive it, offers the potential to modify both symptoms and struc-
tural progression in OA.
CHEMOKINES IN OA
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Purpose: Chemokines represent a large family of small
molecules with conserved structural motifs which act on 7 trans-
membrane receptors. The aim of our work was to investigate
on the major effects mediated by these molecules on cartilage,
bone and synovium in Osteoarthritis.
Methods: Primary human chondrocytes and osteoblasts and
full thickness cartilage or bone samples were obtained from
OA patients undergoing joint arthroplasty. High density or three
dimensional or organ culture, RNA (real time PCR and microar-
ray) and protein (immunohistochemistry, ELISA or ﬂuorescence
bead-based multiplex assays) expression analysis, enzyme ac-
tivity assays, primary human monocytes chemotaxis assays and
functional genomic analysis were employed in our studies.
Results: Some chemokines are constitutively expressed in nor-
mal chondrocytes and strongly unregulated in OA (Borzi RM et
al, FEBS Lett 1999; 455:238). The analysis of the distribution
of the chemokine receptors indicates their expression in the
middle lower layers of the tissue. Chemokine activation is able
to induce DNA synthesis and gene expression and release of
MMPs (MMP-1, MMP-3 and MMP-13) and of other enzymes with
key roles in ECM breakdown, such as NAG, cathepsin B and
aggrecanases (Borzi RM et al, Arthritis Rheum 2000;43:1734;
Mazzetti I et al, Arthritis Rheum 2004;50:112).GROα/CXCL1 in-
duces chondrocyte apoptosis in chondrocytes cultured in vitro or
in the context of their native ECM (Borzi RM et al, Arthritis Rheum
2002;46:3201).This feature is in keeping with the ability reported
for GROα/CXCL1 and IL-8/CXCL8 to promote chondrocyte hy-
pertrophy thus pushing the chondrocytes beyond the status of
“maturational arrest” in chondrogenesis, kept in normal healthy
cartilage. Noteworthy, GROα/CXCL1 induced chondrocyte hy-
pertrophy requires a co-receptor role of chondroitin-sulphate and
is inhibited by soluble CS possibly via a scavenging activity
(Olivotto E et al, J Cell Physiol 2007; 210: 417).
Chemokines can also affect the underlying bone contributing to
the thickening which takes place in OA. IP-10/CXCL10 and BCA-
1/CXCL13 up regulates gene expression of alkaline phosphatase
and collagen type I and also alkaline phosphatase activity (Lisig-
noli G et al, J Cell Physiol 2006; 206:78-85) in osteoblasts derived
from OA patients. With regards to chemokine effects on the syn-
ovium, chemokines may likely contribute to the recruitment of
inﬂammatory cells into the synovial membrane and into the syn-
ovial ﬂuid. Recent experiments with primary human monocytes
(previously shown to be the prevalent cell type in OA synovial
ﬂuid) revealed that MCP-1 is the chemokine most closely asso-
ciated with in vitro chemotaxis, and that it is dependent on both
NF-κB activating kinases.
Conclusions: Chemokines contribute to cartilage pathophys-
iology through autocrine and paracrine loops and medi-
ate a crosstalk among the joint compartments. Since many
chemokines are produced by normal chondrocytes, a detailed
gene expression analysis of chemokines and receptors in nor-
mal and OA cartilage as well as in chondrocyte differentiation
or endochondral ossiﬁcation could help to distinguish members
of this family with physiological functions from chemokines that
deserve to be targeted for therapeutic intervention.
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EVOLVING INDICATIONS FOR JOINT REPLACEMENT
SURGERY IN OA: HIP, KNEE AND ANKLE
V. Goldberg
Case Western Reserve University, Cleveland, OH
Purpose: Total joint arthroplasty has become a reproducible
surgical treatment for osteoarthritis with excellent outcomes. In
2003 approximately 418,000 total knee replacements and over
220,000 hip replacements were performed in the U.S. and this
number is increasing at a rate of 11% for knee replacement and
2.5% for hip replacement per year. During the last decade the
indications for both of these procedures has widened.
Methods: Previously younger and very elderly patients with
OA were discouraged from having total hip or knee replace-
